Advertisement

Erythema Multiforme and Stevens-Johnson Syndrome

  • Mohamed Badawy Abdel-Naser
Chapter

Abstract

Erythema multiforme (EM) is an acute, self-limited, occasionally recurring skin disease considered to be a type IV hypersensitivity reaction to certain infections, medications, and other triggering factors. The skin disease may present within a wide spectrum of severity: EM minor is characterized by pathognomonic target- or iris-like cutaneous lesions with minimal or no mucosal involvement, whereas EM major shows extensive involvement of the mucosal membranes and frequently systemic symptoms. The timely affection of skin and mucous membranes in EM has created confusion with other severe dermatoses, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). In recent years, evidence has been provided that EM major and SJS/TEN are separate entities clinically manifested with similar cutaneous and mucosal involvement differing not only in severity but also in several demographic characteristics and causes [1, 2].

References

  1. 1.
    Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92–6.CrossRefPubMedGoogle Scholar
  2. 2.
    Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Huff JC. Erythema multiforme and latent herpes simplex infection. Semin Dermatol. 1992;11:207–10.PubMedGoogle Scholar
  4. 4.
    Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J. 2003;9:1.PubMedGoogle Scholar
  5. 5.
    Langley A, Anooshiravani N, Kwan S, et al. Erythema multiforme in children and Mycoplasma pneumoniae aetiology. J Cutan Med Surg. 2016;20:453–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Huff JC. Erythema multiforme. Dermatol Clin. 1985;3:141–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Joseph TI, Vargheese G, George D, et al. Drug induced oral erythema multiforme: a rare and less recognized variant of erythema multiforme. J Oral Maxillofac Pathol. 2012;16:14514–8.CrossRefGoogle Scholar
  8. 8.
    Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012;51:889–902.CrossRefPubMedGoogle Scholar
  9. 9.
    Kokuba H, Aurelian L, Burnett J. Herpes simplex virus associated erythema multiforme (HAEM) is mechanistically distinct from drug-induced erythema multiforme: interferon-gamma is expressed in HAEM lesions and tumor necrosis factor-alpha in drug-induced erythema multiforme lesions. J Invest Dermatol. 1999;113:808–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Lemak MA, Duvic M, Bean SF. Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol. 1986;15:50–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol. 1995;132:267–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Kerob D, Assier-Bonnet H, Esnault-Gelly P, et al. Recurrent erythema multiforme unresponsive to acyclovir prophylaxis and responsive to valacyclovir continuous therapy. Arch Dermatol. 1998;134:876–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5:39.  https://doi.org/10.1186/1750-1172-5-39.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. J Plast Reconstr Aesthet Surg. 2016;69:e119–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Tan SK, Tay YK. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. Acta Derm Venereol. 2012;92:62–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Saka B, Kombaté K, Mouhari-Toure A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases. Med Trop (Mars). 2010;70:255–8.Google Scholar
  17. 17.
    Saka B, Barro-Traoré F, Atadokpédé FA, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. Int J Dermatol. 2013;52:575–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCARstudy. J Invest Dermatol. 2008;128:35–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527–31.CrossRefPubMedGoogle Scholar
  20. 20.
    Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg. 2005;58:504–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Yamane Y, Matsukura S, Watanabe Y, et al. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients—treatment and outcome. Allergol Int. 2016;65:74–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Hirahara K, Kano Y, Sato Y, et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. J Am Acad Dermatol. 2013;69:496–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Valeyrie-Allanore L, Wolkenstein P, Brochard L, et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163:847–53.CrossRefPubMedGoogle Scholar
  24. 24.
    Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71:278–83.CrossRefPubMedGoogle Scholar
  25. 25.
    Smith SD, Dodds A, Dixit S, et al. Role of nanocrystalline silver dressings in the management of toxic epidermal necrolysis (TEN) and TEN/Stevens-Johnson syndrome overlap. Australas J Dermatol. 2015;56:298–302.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Mohamed Badawy Abdel-Naser
    • 1
  1. 1.Department of Dermatology and VenereologyAin Shams UniversityCairoEgypt

Personalised recommendations